BDH Industries
- Market cap
- ₹ 246 Cr.
- P/E
- 20.4x
- P/B
- 3.32x
- 52-week range
- 340.15 – 610
- ROE
- 15%
- ROCE
- 20%
- Dividend yield
- 1.1%
- Debt / equity
- 0.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
BDH Industries Limited is engaged in the manufacturing of pharmaceuticals. The Company is also involved in the manufacturing of therapeutic formulations covering a range of pharmaceuticals. Its segments include Pharmaceuticals, and Renewable Energy. The Company is also engaged in the operations of renewable energy, by way of two wind turbines having capacity of 0.8 megawatts (MW) each located at Jaisalmer, Rajasthan. Its products include Analgesics, Antacids, Antibacterial, Anticoagulants, Anticonvulsants, Antifungals, Antihelmentinics, Antiasthmatic, Antimalarials, Antipsychotics and others. Its products include formulations, such as Fentanyl Citrate Injection USP, KALPANJAN Forte Pain Balm, Compound Magnesium Trisilicate Tablets BP, Alcoholic Iodine Solition BP, COLD Syrup, Dicyclomine Hydrochloride Injection, and Aciclovir Cream BP. Its specialty formulations include Morphine Sulphate Slow-Release Tablets 15mg, Sulfasalazine Delayed release tablets U.S.P. 500mg, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →BDH Industries against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)20.4 against a typical 34.3: cheaper than most peers (1st = cheapest).61st of 220
- Sales growth+20.2% against a typical +15.6% from a year earlier.79th of 197
- Profit growth+48.6% against a typical +18.9% from a year earlier.52nd of 160
- Share price, 3 months−26.4% against a typical −0.5%.191st of 200
- Size₹ 246 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).112th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 21 | 27 | 16 | 16 | 16 | 18 | 19 | 19 | 29 | 29 | 22 |
| Expenses | 16 | 18 | 23 | 14 | 13 | 13 | 15 | 17 | 16 | 25 | 25 | 19 |
| Operating Profit | 3 | 3 | 4 | 2 | 3 | 4 | 3 | 2 | 3 | 4 | 4 | 3 |
| OPM % | 16.4% | 16.6% | 14.1% | 12.1% | 18.8% | 21.8% | 17.2% | 11.4% | 17.6% | 14.4% | 14.5% | 15.5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 3 | 4 | 4 | 2 | 3 | 4 | 3 | 2 | 4 | 5 | 5 | 4 |
| Tax % | 26.6% | 25.1% | 25.3% | 25.2% | 25.2% | 25.1% | 26.8% | 25% | 27.8% | 23% | 37.3% | 26.3% |
| Net Profit | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| EPS in Rs | 4.36 | 4.83 | 5.14 | 2.73 | 4.19 | 4.88 | 4.32 | 3.18 | 4.55 | 6.06 | 5 | 4.72 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 8%
- 5 Years
- 11%
- 3 Years
- 9%
- TTM
- 45%
- 10 Years
- 13%
- 5 Years
- 11%
- 3 Years
- 10%
- TTM
- 23%
- 10 Years
- 21%
- 5 Years
- 32%
- 3 Years
- 36%
- TTM
- —
- 10 Years
- 15%
- 5 Years
- 15%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| BDH Industries | ₹ 415.00 | ₹ 246 Cr. | 20.4x | 3.3x | 15% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Jayashree Nair
- Executive Chairperson of the Board, Managing Director
- Nikita Phatak
- Compliance Officer, Company Secretary
- S. C. Kachhara
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.